Brachytherapy is a form of radiation treatment aimed at a short distance from the site of the tumor. In this type of treatment, radioactive seeds are placed within the cancerous tissue to attack it directly without harming the surrounding tissues. Patients with gynecological, breast, and prostate cancer are likely candidates for receiving the treatment.
High-dose rate (HDR) and low-dose rate (LDR) brachytherapy are two forms of the treatment with varying levels of radiation strength and application time. Cases of pulmonary and head and neck cancer are being treated with HDR due to being cost-effective than its counterpart. Safety guidelines for radiation doses by the National Investigation Agency (NIA) and the U.S. Environmental Protection Agency (EPA) can minimize health risks of patients, improving the treatment adoption rate among patients.
Minimize Hospital Stay
Major applications of brachytherapy are breast cancer, prostate cancer, gynecological cancer, and others. The breast cancer segment is anticipated to expand at a CAGR exceeding 5% from 2014 to 2025 owing to high incidence of breast cancer. According to the American Cancer Society, breast cancer is one of the most common types of cancer in the U.S. affecting women, with the possibility of more than 250,000 cases in 2017.
The prostate cancer segment is anticipated a decent growth rate due to the use of brachytherapy to treat this type of cancer in developed countries. According to the American Cancer Society, nearly 161,370 cases of prostate cancer are expected in 2017 due to high levels of obesity and unhealthy lifestyles followed by patients. Companies are providing real-time solutions to patients to reduce hospital stay. An instance includes the Real-time Prostate Solutions by Elekta AB that completes the session in a single day without harming any organs of the patient.
Market Insights
The global brachytherapy market is projected to reach a market capitalization of USD 486.9 million by 2025, according to a report by Grand View Research, Inc. It is expected to exhibit a CAGR of 4.06% over the forecast period (2014-2025). Rise in numbers of the geriatric populace, sedentary lifestyles of patients, and unmet cancer needs of patients in low- and middle-income countries.
Preference of minimally invasive surgery and favorable medical reimbursement schemes to tackle cases of prostate cancer and age-related macular degeneration (AMD) are factors predicted to augur market growth over the forecast period. The emerging markets of China, India, and Brazil are expected to open up new avenues for growth. Key market players include IsoRay Medical, Inc.; Elekta AB; Eckert & Ziegler BEBIG S.A.; and Theragenics Corporation.
In-Depth Research Report On Brachytherapy Market:
https://www.grandviewresearch.com/industry-analysis/brachytherapy-devices-market
No comments:
Post a Comment